Latest Research, Industry, Medical and Scientific News
Acupuncture outperforms drug therapy for the treatment of mild to moderate female stress urinary incontinence (FSUI). Researchers from Weihai City Hospital of Traditional Chinese Medicine conclude that electroacupuncture is effective for the control of FSUI. In the study, an electroacupuncture treatment group produced a positive patient outcome rate of 86.7%. The drug control group produced a 68.9% positive patient outcome rate for the treatment of FSUI. The electroacupuncture group had a significantly higher complete recovery rate and total effective rate. Read more.
Source: Health CMi, May 9, 2017
In order to help normalize the topic of bladder leaks, Always Discreet is working with retailers to educate women nationwide. As an example, Procter & Gamble’s Always Discreet brand on Thursday worked with Walmart to launch a new, inspirational video to help women understand how common bladder leaks are and to rethink their negative feelings. “Because many women avoid talking about their bladder leaks, they can often feel alone in their experience, embarrassed to bring up the topic, and hesitant to shop for and wear incontinence products,” stated Barbara Hannah Grufferman, positive living expert, author and Always Discreet spokesperson. “Over the years, I’ve spoken to thousands of women around the country who have bladder leaks, and most women don’t realize how common and normal it is. The good news is that once women realize how many other women experience it too, they feel better about it and themselves,” she said. “That’s what’s been captured in this video, and the hope is that women watch it, make that connection for themselves and feel more confident, empowered and compelled to live their best lives and stand in solidarity with the many other women who experience bladder leaks too.” Read more.
Source: Drug Store News, May 4, 2017
Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a study. While patients reported a decline in these quality of life measures immediately after brachytherapy, they achieved a full recovery within six months. Brachytherapy involves inserting radioactive seeds in or near tumor to kill it. The research, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was published in the Journal of Radiation Oncology, Biology, Physics. “This study reinforces the position of Cesium 131 as an effective, patient-friendly treatment for localized prostate cancer,” Bill Cavanagh, chief scientific officer of the brachytherapy company IsoRay, said in a news release. “This is especially important as multiple studies are emerging that strongly suggest that the inclusion of brachytherapy must be considered for the treatment of high-risk prostate cancer – the toughest localized prostate cancer to cure.” Read more.
Source: Prostate Cancer News Today, May 4, 2017
Pixie Scientific announced today that it has completed the FDA registration for Pixie Smart Pads and has begun shipping to Early Access customers. The Class I medical device utilizes a patented sensor and software platform to unobtrusively monitor incontinent seniors for an analyte commonly associated with urinary tract infections (UTIs). Pixie Scientific is a healthcare platform technology company focused on improving outcomes by connecting populations at risk with unobtrusive health monitoring—a field Pixie refers to as Connected Care. Pixie’s patented platform consists of a biosensor, a mobile app, and secure cloud architecture which utilizes machine learning for analysis and disseminates information to remote care teams. Clinicians can use this information, along with other symptoms, to order additional patient evaluation or more specific diagnostics in a timely manner—which may lower the rate of co-morbidities and hospital admissions due to UTIs and improve antibiotic stewardship. Read more.
Source: PRNewswire, May 3, 2017
Global medical technology company ConvaTecGroup announced the US launch of the Flexi-Seal PROTECT Fecal Management System on Tuesday, following receipt of 510(k) clearance from the US Food and Drug Administration. The FTSE 100 firm said Flexi-Seal PROTECT FMS was the latest addition to the company’s “market-leading range” of advanced systems developed to manage acute fecal incontinence, and help to reduce the associated risks of skin breakdown and spread of C. difficile infection. Read more.
Source: digitallook.com, May 2, 2017
SCA, a company know in the HME industry for its hygiene and incontinence products, such as TENA, will be splitting into two companies, SCA and Essity, with Essity being the company working in the healthcare market. SCA was founded 1929 in Sweden as a forest products company, and over the years the company not only expanded into the international market, but diversified its range of offerings to include incontinence products and other offerings. Most recently, it acquired well-known BSN medical. Eventually, SCA’s health offerings began to eclipse its forest products division. As of 2016, 86 percent of SCA serves the global hygiene and health market, while only 14 percent offers forest products. Moreover, synergies between the two operations have diminished over time, according to SCA. Read more.
Source: HME Business, April 13, 2017